Intestinal Research

Kristine Paridaens

2 Articles

IBD

The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitis: Jae Hee Cheon, Kristine Paridaens, Sameer Al Awadhi, Jakob Begun, John R Fullarton, Edouard Louis, Fernando Magro, Juan Ricardo Marquez, Alexander R Moschen, Neeraj Narula, Grazyna Rydzewska, Axel U Dignass, Simon PL Travis; Intest Res 2023;21(1):161-167. Published online April 18, 2022; DOI: https://doi.org/10.5217/ir.2022.00006

PDF Supplementary Material PubReader ePub

Citations

Citations to this article as recorded by

New genetic biomarkers predicting 5-aminosalicylate-induced adverse events in patients with inflammatory bowel diseases
Jihye Park, I. Seul Park, Ji Hyung Kim, Jung Hyun Ji, Soo Jung Park, Jae Jun Park, Tae Il Kim, Seung Won Kim, Jae Hee Cheon
Therapeutic Advances in Gastroenterology.2024;[Epub] CrossRef

4,520 View
530 Download
1 Web of Science
1 Crossref

IBD

Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy–Access to Rapid Treatment (iSTART) approach: Silvio Danese, Rupa Banerjee, JR Fraser Cummings, Iris Dotan, Paulo G Kotze, Rupert Wing Loong Leong, Kristine Paridaens, Laurent Peyrin-Biroulet, Glyn Scott, Gert Van Assche, Jan Wehkamp, Jesús K Yamamoto-Furusho; Intest Res 2018;16(4):522-528. Published online October 16, 2018; DOI: https://doi.org/10.5217/ir.2018.00073

Abstract PDF Supplementary Material PubReader ePub

Symptomatic ulcerative colitis (UC) can be a chronic, disabling condition. Flares in disease activity are associated with many of the negative impacts of mild-to-moderate UC. Rapid resolution of flares can provide benefits to patients and healthcare systems. i Support Therapy–Access to Rapid Treatment (iSTART) introduces patient-centered care for mild-to-moderate UC. iSTART provides patients with the ability to self-assess symptomology and self-start a short course of second-line treatment when necessary. An international panel of experts produced consensus statements and recommendations. These were informed by evidence from systematic reviews on the epidemiology, mesalazine (5-ASA) treatment, and patient use criteria for second-line therapy in UC. Optimized 5-ASA is the first-line treatment in all clinical guidelines, but may not be sufficient to induce remission in all patients. Corticosteroids should be prescribed as second-line therapy when needed, with budesonide MMX® being a preferred steroid option. Active involvement of suitable patients in management of UC flares has the potential to improve therapy, with patients able to show good accuracy for flare self-assessment using validated tools. There is a place in the UC treatment pathway for an approach such as iSTART, which has the potential to provide patient, clinical and economic benefits.

Citations

Citations to this article as recorded by

Sodium orthovanadate protects against ulcerative colitis and associated liver damage in mice: insights into modulations of Nrf2/Keap1 and NF-κB pathways
Gurpreet Kaur, Ajay Singh Kushwah
Naunyn-Schmiedeberg's Archives of Pharmacology.2025; 398(2): 1557. CrossRef
Management and treatment optimization of patients with mild to moderate ulcerative colitis
Ferdinando D’Amico, Ernesto Fasulo, Vipul Jairath, Kristine Paridaens, Laurent Peyrin-Biroulet, Silvio Danese
Expert Review of Clinical Immunology.2024; 20(3): 277. CrossRef
Practical management of mild-to-moderate ulcerative colitis: an international expert consensus
Ferdinando D’Amico, Fernando Magro, Axel Dignass, Sameer Al Awadhi, Ana Gutierrez Casbas, Natália Sousa Freitas Queiroz, Grażyna Rydzewska, Byong Duk Ye, Zhihua Ran, Ailsa Hart, Vipul Jairath, Gionata Fiorino, Laurent Peyrin-Biroulet, Silvio Danese
Expert Review of Gastroenterology & Hepatology.2024; 18(8): 421. CrossRef
Framework of IBD Care Delivery Across Ages
Stefan Delen, Susanna Jaghult, Irina Blumenstein, Lieven Pouillon, Peter Bossuyt
Journal of Crohn's and Colitis.2024; 18(Supplement): ii55. CrossRef
Effectiveness of Mesalamine in Patients With Ulcerative Colitis: A Systematic Review
Yurianna Santos, Arturo P Jaramillo
Cureus.2023;[Epub] CrossRef
Encoding bacterial colonization and therapeutic modality by wrapping with an adhesive drug-loadable nanocoating
Huilong Luo, Feng Wu, Xinyue Wang, Sisi Lin, Mengmeng Zhang, Zhenping Cao, Jinyao Liu
Materials Today.2023; 62: 98. CrossRef
iSTART-II: An Update on the i Support Therapy–Access to Rapid Treatment (iSTART) Approach for Patient-Centered Therapy in Mild-to-Moderate Ulcerative Colitis
Ferdinando D’Amico, Fernando Magro, Benedicte Caron, Axel Dignass, Vipul Jairath, Ailsa Hart, Paulo Gustavo Kotze, Kristine Paridaens, Sameer Al Awadhi, Taku Kobayashi, Britta Siegmund, Laurent Peyrin-Biroulet, Silvio Danese
Journal of Clinical Medicine.2023; 12(3): 1142. CrossRef
A review article of inflammatory bowel disease treatment and pharmacogenomics
Nashwa Eltantawy, Islam Abd El-Hamid El-Zayyadi, Ahmed A. Elberry, Layla M. Salah, Mohamed E. A. Abdelrahim, Amira B. Kassem
Beni-Suef University Journal of Basic and Applied Sciences.2023;[Epub] CrossRef
Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis
Axel U. Dignass, Kristine Paridaens, Sameer Al Awadhi, Jakob Begun, Jae Hee Cheon, John R. Fullarton, Edouard Louis, Fernando Magro, Juan Ricardo Marquez, Alexander R. Moschen, Neeraj Narula, Grazyna Rydzewska, Simon P. L. Travis
Scandinavian Journal of Gastroenterology.2022; 57(4): 424. CrossRef
Needs and preferences of patients regarding atopic dermatitis care in the era of new therapeutic options: a qualitative study
Linde E. M. de Wijs, Sven van Egmond, Arjan C. A. Devillers, Tamar Nijsten, DirkJan Hijnen, Marjolein Lugtenberg
Archives of Dermatological Research.2022; 315(1): 75. CrossRef
Mesalazine in the induction of clinical and endoscopic remission of mild and moderate ulcerative colitis
M. V. Shapina
Meditsinskiy sovet = Medical Council.2022; (15): 90. CrossRef
Budesonide MMX in the Treatment of Ulcerative Colitis: Current Perspectives on Efficacy and Safety
Giovanni Maconi, Deborah Camatta, Rosanna Cannatelli, Francesca Ferretti, Anna Carvalhas Gabrielli, Sandro Ardizzone
Therapeutics and Clinical Risk Management.2021; Volume 17: 285. CrossRef
High Serum Osmolality May Predict the Disease Severity in Patients with Acute Ulcerative Colitis
Abdussamed VURAL, Aslı VURAL, Selahattin VURAL, Selim TURFAN, Ahmet Cumhur DÜLGER
Online Türk Sağlık Bilimleri Dergisi.2020; 5(2): 324. CrossRef
The Efficacy and Safety of Mesalamine and Probiotics in Mild‐to‐Moderate Ulcerative Colitis: A Systematic Review and Meta‐Analysis
Chunying Tian, Yang Huang, Xiaoxia Wu, Chuhan Xu, Huaien Bu, Hongwu Wang, Jairo Kennup Bastos
Evidence-Based Complementary and Alternative Medicine.2020;[Epub] CrossRef
Teleconsulta en la pandemia por Coronavirus: desafíos para la telemedicina pos-COVID-19
Juan Ricardo Márquez Velásquez
Revista Colombiana de Gastroenterología.2020; 35(Supl. 1): 5. CrossRef
Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis
Virginia Solitano, Ferdinando D’Amico, Gionata Fiorino, Kristine Paridaens, Laurent Peyrin-Biroulet, Silvio Danese
Journal of Clinical Medicine.2020; 9(9): 2905. CrossRef
A clinical case of ulcerative colitis in a patient with viral hepatitis
E. D. Kosmachova, M. S. Iakovenko, K. A. Yumukian
South Russian Journal of Therapeutic Practice.2020; 1(3): 95. CrossRef
Case Report on Ulcerative Colitis in 16 year girl
MD.Salma MD.Salma, Y.Siva Y.Siva , , J.Bhargava Narendra , J.Bhargava Narendra
World Journal of Current Medical and Pharmaceutical Research.2020; : 287. CrossRef

12,063 View
568 Download
16 Web of Science
18 Crossref

Author index